Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II Study of Cetuximab in Refractory or Relapsed Multiple Myeloma
2005-005612-24Phase 2Terminated
- Sponsor
- University of Cologne
- Start
- Apr 2006
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of cetuximab in multiple myeloma (MM), sponsored by University of Cologne. Primary endpoint: Overall response rate. Started Apr 2006; status: terminated.
02
Drugs
cetuximab
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on 2005-005612-24.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-005612-24.